Albireo Pharma Inc Actions en circulation
Quel est le Actions en circulation de Albireo Pharma Inc?
Le Actions en circulation de Albireo Pharma Inc est 20.701M
Quelle est la définition de Actions en circulation?
Les actions en circulation sont toutes les actions d'une société ou d'un actif financier qui ont été autorisées, émises et achetées par les investisseurs et qui sont détenues par eux.
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
Actions en circulation des entreprises dans Health Care secteur sur NASDAQ par rapport à Albireo Pharma Inc
Que fait Albireo Pharma Inc?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Entreprises avec actions en circulation similaire à Albireo Pharma Inc
- Hemisphere Media Inc a Actions en circulation de 20.680M
- Backstageplay a Actions en circulation de 20.688M
- Integrated Media Technology a Actions en circulation de 20.688M
- ad pepper media International NV a Actions en circulation de 20.691M
- Seanergy Maritime Corp a Actions en circulation de 20.699M
- CHS a Actions en circulation de 20.700M
- Albireo Pharma Inc a Actions en circulation de 20.701M
- Intercontinental Gold and Metals a Actions en circulation de 20.709M
- Lefteris Acquisition a Actions en circulation de 20.710M
- Mineral Hill Industries a Actions en circulation de 20.725M
- Monte Carlo Fashions a Actions en circulation de 20.732M
- VPC Impact Acquisition a Actions en circulation de 20.737M
- Sphere 3D Corp a Actions en circulation de 20.743M